Cargando…

A 16-gene signature associated with homologous recombination deficiency for prognosis prediction in patients with triple-negative breast cancer

Homologous recombination deficiency (HRD) commonly occurs in breast cancer, which is the second cause of cancer death in women with a high rate of relapse and poor outcomes. Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Thus, we aim to develop a prognostic sig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Daodu, Shi, Yifeng, Huang, Hanyang, Zhao, Qijiong, He, Yongyue, Su, Wenzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096232/ https://www.ncbi.nlm.nih.gov/pubmed/35950033 http://dx.doi.org/10.1515/med-2022-0475

Ejemplares similares

Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency
por: Kawazu, Masahito, et al.
Publicado: (2017)

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency
por: Liao, Gaoming, et al.
Publicado: (2022)

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells
por: Mani, Chinnadurai, et al.
Publicado: (2019)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
por: Chen, Yimeng, et al.
Publicado: (2023)

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
por: ter Brugge, Petra, et al.
Publicado: (2023)

Development and validation of an inflammatory response-related signature in triple negative breast cancer for predicting prognosis and immunotherapy
por: Guo, Yangyang, et al.
Publicado: (2023)

The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
por: Gu, Yayun, et al.
Publicado: (2021)

Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer
por: Wu, Xin, et al.
Publicado: (2022)

An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer
por: Zhang, Bo, et al.
Publicado: (2023)

Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers
por: Domagala, Pawel, et al.
Publicado: (2015)

Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer
por: Liao, Gaoming, et al.
Publicado: (2021)

Homologous recombination deficiency and glycolysis‐related pathway in adjuvant chemotherapy for triple‐negative breast cancer: A genomic landscape and biomarker assessment of the PATTERN trial
por: Zhu, Si‐Yuan, et al.
Publicado: (2021)

Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
por: Ueno, Takayuki, et al.
Publicado: (2022)

Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer
por: Sun, Xiaorui, et al.
Publicado: (2022)

Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients
por: Peng, Wei, et al.
Publicado: (2022)

Multi-scale characterisation of homologous recombination deficiency in breast cancer
por: Jacobson, Daniel H., et al.
Publicado: (2023)

Identification of a prognosis-associated signature associated with energy metabolism in triple-negative breast cancer
por: Li, Chao, et al.
Publicado: (2020)

A Novel Platelet-Related Gene Signature for Predicting the Prognosis of Triple-Negative Breast Cancer
por: Xie, Jindong, et al.
Publicado: (2022)

Identification of a novel glycolysis-related prognosis risk signature in triple-negative breast cancer
por: Ruan, Yuxia, et al.
Publicado: (2023)

Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis
por: Zhang, Liulu, et al.
Publicado: (2022)

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
por: Masuda, Norikazu, et al.
Publicado: (2021)

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature
por: Batalini, Felipe, et al.
Publicado: (2023)

Homologous Recombination Related Signatures Predict Prognosis and Immunotherapy Response in Metastatic Urothelial Carcinoma
por: Li, Pan, et al.
Publicado: (2022)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level
por: Zhuang, Shuping, et al.
Publicado: (2021)

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration
por: Tsang, Erica S., et al.
Publicado: (2023)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Homologous Recombination Deficiencies and Hereditary Tumors
por: Yamamoto, Hideki, et al.
Publicado: (2021)

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Methylation‐ and homologous recombination deficiency‐related mutant genes predict the prognosis of lung adenocarcinoma
por: Nie, Guang‐Jie, et al.
Publicado: (2022)

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
por: Póti, Ádám, et al.
Publicado: (2019)

Clinical features and prognosis of triple-negative breast cancer
por: Sanz, M Izquierdo, et al.
Publicado: (2009)

T-cadherin is associated with prognosis in triple-negative breast cancer
por: Kong, De-Di, et al.
Publicado: (2017)

Distinct microbiological signatures associated with triple negative breast cancer
por: Banerjee, Sagarika, et al.
Publicado: (2015)

SLC26A4 correlates with homologous recombination deficiency and patient prognosis in prostate cancer
por: Luo, Cong, et al.
Publicado: (2022)

Pan-cancer landscape of homologous recombination deficiency
por: Nguyen, Luan, et al.
Publicado: (2020)

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
por: Wattenberg, Max M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gmbcsv36s4e8a0ta9mu7bleme8